Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

Inclusion Criteria: * Newly diagnosed primary AML patients. Diagnostic criteria refer to the 2022 WHO classification. * Age between 18 and 60 years old. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix 2). * Cardiac ultrasound LVEF ≥ 45%. * Creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula or measured using a 24-hour urine sample). * Liver function: Aspartate aminotransferase (AST) ≤ 2.5 × ULN\*; Alanine aminotransferase (ALT) ≤ 2.5 × ULN\*; Total bilirubin ≤ 1.5 × ULN\* (\*unless considered due to leukemia infiltration). * Signed informed consent form. Exclusion Criteria: * Acute promyelocytic leukemia (APL). * Relapsed/refractory AML patients. * AML patients with known involvement of the central nervous system (CNS). * Known HIV-infected participants (due to potential drug-drug interactions between antiretroviral drugs and venetoclax). HIV testing will be conducted during screening according to local guidelines or institutional standards.Participants with positive hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Non-active carriers of viral hepatitis or participants with low viral hepatitis viral titers after receiving non-prohibited antiviral therapy will not be excluded. * Participants who have received strong or moderate CYP3A inducers/inhibitors therapy within 7 days prior to starting study treatment. * Participants with New York Heart Association (NYHA) functional classification \> Grade 2. Grade 2 is defined as patients having cardiac disease with no symptoms at rest but experiencing fatigue, palpitations, dyspnea, or angina with ordinary physical activity. * Participants with chronic respiratory disease requiring continuous oxygen therapy. * Patients unable to take oral medications or with malabsorption syndrome. * Presence of uncontrolled systemic infection (viral, bacterial, or fungal). * Participants who have previously received venetoclax treatment and/or are currently participating in any other study involving investigational drugs.